News | April 28, 2010

FDG PET/CT Identifies Aortic Dissection

April 28, 2010 - Molecular imaging can help physicians identify aortic dissection and help guide treatment, according to research published in the May issue of The Journal of Nuclear Medicine.

Dissection occurs when a tear in the wall of the aorta causes blood to flow between the layers of the wall of the aorta and force the layers apart. Aortic dissection is the tenth leading cause of death in Western societies. It is the second most frequent cause of acute chest pain, but it is difficult to identify. However, positron emission tomography (PET) with the imaging agent fluorodeoxyglucose (FDG) and computed tomography (CT) may help determine the age of an aortic dissection, the degree of risk and the need for surgery.

"Many conventional forms of imaging are not able to clearly differentiate between acute and chronic dissection," said Hans-Henning Eckstein, M.D., Ph.D., professor at the Technical University of Munich in Germany and the corresponding author of "Imaging of Acute and Chronic Aortic Dissection by 18F-FDG PET/CT."
He added, "It is critical to patients' survival that doctors are able to verify acute or exclude chronic aortic dissection so they can decide the best course of treatment. [These might be] rushing the patient to surgery in some cases or using beta blockers to lower the blood pressure."

In the Munich study, researchers examined patients who had symptoms of aortic dissection and patients with chronic asymptomatic dissection using FDG PET/CT to acquire images of the affected area, just above the heart. These images were studied to determine the difference between the two forms of aortic dissection. The researchers reported that acute dissection of the aortic wall led to elevated metabolic activity in fresh lacerated segments of the aortic wall, while stable chronic aortic dissection showed no increased metabolic activity.

Researchers speculate that increased metabolic activity in cases of acute aortic dissection is due to repair mechanisms of the aortic wall injury, causing cell activation and accumulation. The low metabolic activity in chronic aortic dissection is due to scar tissue. The searchers concluded further studies are needed to prove these hypotheses.

Reference: Authors of, "Imaging of Acute and Chronic Aortic Dissection by 18F-FDG PET/CT," include: Christian Reeps, Jaroslav Pelisek, Manuela Gurdan, Alexander Zimmermann, Stefan Ockert, and Hans-Henning Eckstein, of the Clinic for Vascular Surgery, Klinikum-rechts-der-Isar, Technische Universität München, Munich, Germany; Ralph A. Bundschuh and Markus Essler, Clinic for Nuclear Medicine, Klinikum-rechts-der-Isar, Technische Universität München, Munich, Germany; and Martin Dobritz, Institute for Radiology, Klinikum-rechts-der-Isar, Technische Universität München, Munich, Germany.

For more information: www.snm.org

Related Content

PET/CT Tracer Identifies Vulnerable Lesions in Non-Small Cell Lung Cancer Patients

Example of a patient with an upper left lung NSCLC: A: FDG; B: FDG PET/CT; C: Planning radiotherapy based on FDG (66Gy) with BTVm (GTV), CTV and PTV; D: PET FMISO E: FMISO PET/CT; F: boost based on the FMISO PET (76Gy) with BTVh (biological hypoxic target volume) and PTV boost. Credit: QuantIF – LITIS EA 4108 – FR CNRS 3638, Henri Becquerel Cancer Center, Rouen, France

News | PET-CT | July 14, 2017
July 14, 2017 — Fluorine-18 (18F)-fluoromisonidazole (FMISO) is a positron emission tomography (PET)...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior

Axial fused 89Zr-5B1 antibody PET/CT image demonstrates focus of uptake in the liver (arrow). Focus of uptake correlates with increased liver metastasis seen on diagnostic CT (red arrow) performed 2 weeks prior. Image courtesy of Christian Lohrmann, Jason Lewis, Wolfgang Weber, Memorial Sloan Kettering Cancer Center; MabVax Therapeutics

News | PET-CT | June 14, 2017
Pancreatic cancer is associated with bleak five-year survival rates and limited treatment options, but new research is...
PET/CT
News | PET-CT | June 12, 2017
Philips announced that it will be showcasing molecular imaging solutions highlighting Philips’ commitment to innovation...
News | PET-CT | June 12, 2017
Siemens Healthineers has announced that the Food and Drug Administration (FDA) has cleared Biograph Horizon Flow...
Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients

Toshiba Medical launches its new Celesteion PUREViSION Edition PET/CT system to help diagnose and treat oncology patients.

News | PET-CT | June 09, 2017
Oncologists have access to advanced imaging technologies for excellent cancer patient care with the new Celesteion...
News | SPECT-CT | June 08, 2017
Siemens Healthineers debuts Symbia Intevo Bold at the 2017 annual meeting of the Society of Nuclear Medicine &...
FALCON Trial of Fluciclovine PET/CT Imaging Stops Recruitment after Successful Interim Analysis
News | Radiopharmaceuticals and Tracers | May 15, 2017
Blue Earth Diagnostics announced that the Trial Steering Committee recommended further recruitment be stopped in the...
Overlay Init